BioAge Labs
BioAge Labs (NASDAQ: BIOA) is a publicly traded Aging Drug Discovery company founded in 2015 and based in Richmond, United States.
Founded in 2015 and headquartered in Richmond, California, BioAge Labs is a clinical-stage biopharmaceutical company co-founded and led by CEO Kristen Fortney that discovers drugs by analyzing human aging cohorts and longitudinal samples. Its platform mines molecular and clinical data from people who age well to nominate targets in metabolism and inflammation. The lead candidate BGE-102 is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor in Phase 1 for cardiovascular risk and retinal diseases including diabetic macular edema, with reported best-in-class hsCRP reductions in interim data. BioAge IPO'd on Nasdaq in September 2024 under ticker BIOA, raising about $198M in gross proceeds.
One of the few public pure-play aging-biology companies, validating human-data-driven target discovery for age-related disease.
bioagelabs.com ↗·Aging Drug Discovery·
United States·public · NASDAQ: BIOA 
